NCT05999240View on ClinicalTrials.gov

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

May 15, 2026

Study Completion Date

May 15, 2026

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]

Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo at Visit 2.

DRUG

Placebo

Placebo for Pimavanserin Tartrate 34 Mg ORAL CAPSILE \[NUPLAZID\]

Trial Locations (2)

10605

NOT_YET_RECRUITING

Center for Autism and the Developing Brain, White Plains

66049

RECRUITING

Wakarusa Research Facility, Lawrence

Sponsors
All Listed Sponsors
collaborator

ACADIA Pharmaceuticals Inc.

INDUSTRY

collaborator

University of Kansas Medical Center

OTHER

collaborator

Research Foundation for Mental Hygiene, Inc.

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

lead

New York State Psychiatric Institute

OTHER